home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

2-day In-person Seminar on How to prepare and submit a Bullet Proof 510(k) and Latest FDA Proposed Changes to the Process at San Francisco, CA

 
  November 23, 2013  
     
 


GlobalCompliancePanel, DoubleTree by Hilton Hotel San Francisco Airport, 835 Airport Blvd., Burlingame, California, 94010-9949, USA
2013-12-12


Overview:

This Two-day course is a primer and overview to the premarket notification process, i.e., a 510(k). A 510(k) is a premarket submission made to FDA to demonstrate that your device to be marketed is at least as safe and effective, that is, substantially equivalent, to a legally marketed device that is not subject to PMA. There are three types of Premarket Notification 510(k) s that may be submitted to FDA: Traditional, Special, and Abbreviated. The Special and Abbreviated 510(k) methods were developed under the "New 510(k) Paradigm" to help streamline the 510(k) review process. Product modifications that could significantly affect safety and effectiveness are subject to 510(k) submission requirements under 21 CFR 807 as well as design control requirements under the Quality System (QS) regulation. Under the QS regulation, all Class II and III devices and certain Class I devices are required to be designed in conformance to 21 CFR 820.30 Design Controls. FDA provides guidance and this course will address key resources when making critical decisions.
For more than 30 years, the 510(k) process has consistently done a good job of protecting patients against unsafe products. The process is well designed to assess the safety and effectiveness of low and moderate risk medical devices whose risks are well understood from experience with similar devices. Various industry trade groups and associations are now somewhat concerned that the number and scope of FDA's recently proposed 510(k) changes could negatively impact the agency's mission to ensure American patients have timely access to safe and effective medical technologies.
In comments submitted to FDA in response to the agency's release in August 2010 of more than 60 proposals to change the 510(k) process, industry has advocated that instead of implementing an extensive list of potentially disruptive proposals, FDA should focus on the proposals the agency has advanced that enjoy broad agreement and consensus, such as: increased reviewer training, development of specific and relevant guidance documents, and enhancements or improvements to the de novo review pathway, among other suggestions. This 1-day primer and course will provide an update to these proposals as appropriate and where we stand but more importantly, provide direction, guidance and clarity on preparing for, executing and submitting your 510(k) application.

Objectives:

1.    Know the differences between the Traditional, Special and Abbreviated submissions

2.    Understand Substantial Equivalence and how it is applied

3.    Who is required to submit the application to FDA?

4.    Where to submit the 510(k) and what to expect with the review and approval process

5.    When it is and is not required if you are a device company

6.    Exemptions to the submission process and special considerations

7.    How to locate a "predicate" device and go through the content and format of the 510(k)

8.    Understand the De Novo process and the expectations for possibly marketing a low risk device

9.    Understand the potential impact of FDA's proposed changes to the 510(k) process and why manufacturers need to pay attention

Day 1 – Agenda

Lecture 1: Introduction and Regulatory Background

1.    There is no 510(k) form; however, 21 CFR 807 Subpart E describes requirements for a 510(k) submission.

2.    Current trends with the 510(k) process.

Lecture 2: The Process

1.    Who is required to submit a 510(k?)

2.    When a 510(k) is not required

3.    When a 510(k) is required

4.    Locating and justifying the Predicate

5.    Substantial Equivalence and demonstration of SE to another legally U.S. marketed device

6.    How to Prepare Submissions

7.    510(k) Submission Methods

8.    List of forms associated with Premarket Notification 510(k) submissions

9.    Deciding When to Submit a 510(k) for a Change to an Existing Device

10. What happens if FDA requires additional information and data and your responsibilities

Day 2 – Agenda

Lecture 3: Interactive Q&A, Wrap-Up and Adjourn

1.    Q&A with all participants and attendees

2.    Group discussion and review of recent 510(k) clearances and proposals and recommendations between FDA and industry

3.    Discussion Points: some of the recommendations have included, but not limited to, redefining fundamental terms, limiting use of predicates, greater authority to rescind 510(k)s, etc.

4.    510(k) Frequently Asked Questions

5.    Attendees and participants should be prepared to address any issues and challenges as experienced on behalf of their company in this open-forum and interactive session

Who Will Benefit:

CEOs &CFOs in medical device companies

VPs, Directors and Heads of Regulatory Affairs

VPs, Directors and Heads of Clinical Affairs

Senior and line Marketing and Sales Management

Regulatory Consultants

Risk Managers

Engineering & R&D

Professionals involved with premarket notification to the FDA

R&D personnel involved in approving the design of medical devices

Medical device sales and marketing personnel

Production & Operations

DATE, VENUE & PRICE:

Location: San Francisco, CA| 12th & 13th December 2013| 9 AM to 6 PM

Venue: DoubleTree by Hilton Hotel San Francisco Airport

Price: $1,295.00

Register now and save $200. (Early Bird)

Until October 25, Early Bird Price: $1,295.00

From October 26 to December 10, Regular Price: $1,495.00

 

 
 
Organized by: GlobalCompliancePanel
Invited Speakers:

David R. Dills, Regulatory & Compliance Consultant with more than 24 years of hands-on experience and a proven track record within the FDA regulated industry, has an extensive regulatory and compliance background with Class I/II/III and IVD devices, pharmaceutical operations, and manages activities within the global regulatory and compliance space. He manages quality, regulatory and compliance projects with multiple competing priorities having a direct impact on site operations and commercial opportunities and develops strategies for governmental approval to introduce new products to market, provides guidance on regulatory and compliance requirements and prepares/reviews worldwide submissions/dossiers/technical files and addresses global regulatory requirements.

 

Register Now 

 
Deadline for Abstracts: 2013-12-12
 
Registration:

Contact Information: 

Event Coordinator

Toll free: 1800 447 9407

Fax: 302 288 6884

Email: support@globalcompliancepanel.com

Website: https://www.globalcompliancepanel.com

LIVE CHAT SUPPORT ALSO - http://www.globalcompliancepanel.com/chat/client.php

Net Zealous LLC,

DBA GlobalCompliancePanel,

161 Mission Falls Lane,

Suite 216, Fremont, CA 94539, USA 

Register Now  

E-mail: support@globalcompliancepanel.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.